UNLABELLED In patients with progressive metastatic (or recurrent) differentiated thyroid carcinoma (DTC) who do not respond to radioiodine therapy or do not show uptake on radioiodine scintigraphy, treatment options are few. Because these tumors may express somatostatin receptors, peptide receptor radionuclide therapy might be effective. We evaluated the therapeutic efficacy of the radiolabeled...

Objective(s): 68Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT) has shown promising results in imaging of neural crest tumors (NCT). Herein, we compared the performance of 68Ga-DOTATATE PET/CT and 131I-MIBG single photon emission computed tomography (SPECT)/CT in the initial diagnosis, staging and follow-up of pa...

OBJECTIVE We aimed to evaluate the value of somatostatin receptor imaging (SRI) with In-111 octreotide and Ga-68 DOTATATE in localizing ectopic ACTH producing tumors. METHODS Nineteen patients who had In-111 octreotide somatostatin receptor scintigraphy (SRS) and/or Ga-68 DOTATATE PET-CT to localize ectopic ACTH producing tumors between the years 2000 and 2012 were included retrospectively in...

Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogues. We have treated over 1,200 patients with peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE...

در پژوهش حاضر به بررسی امکان تولید رادیونوکلید لوتسیوم-177، Lu177، رآکتور تحقیقاتی تهران، TRR، پرداخته شده است. Lu177 با داشتن ویژگی‏های واپاشی هسته‏ای مناسب و هم‏چنین رفتار شیمیایی مطلوب، یک ایده‏آل جهت تهیه رادیوداروهای درمانی برخی از حاوی حال کشور درمان انواع سرطان استفاده می‏شود بسیاری آن­ها تحت آزمایشات بالینی هستند. را می‏توان یا مستقیماً طریق واکنش Lu177Lu(n,γ)176 طور غیرمستقیم طی کرد. با...

68Ga-labeled octreotide analogs, including DOTATOC, DOTATATE and DOTANOC, are very useful PET radiopharmaceuticals in the management of neuroendocrine tumors (NETs). However, a considerable number of malignancies beyond NETs, including lymphomas, express somatostatin receptors and are eligible to accumulate radiolabeled octreotide analogs, leading to misleading findings on somatostatin receptor...

Introduction: Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms, majority of which express somatostatin (SST) receptors. Recently, with the widespread use of positron emission tomography/computed tomography (PET/CT) and development of novel PET tracers like Ga-68 DOTA peptide which specifically bind to somatostatin receptors (SSTR), Ga-68 DOTA peptide PET/CT is used in manageme...

BACKGROUND (177)Lu-DOTATATE is a valuable treatment option for patients with advanced neuroendocrine tumours overexpressing somatostatin receptors. Though well tolerated in general, bone marrow toxicity can, besides renal exposure, become dose limiting and affect the ability to sustain future therapies. The aim of this study was to develop a novel planar image-based method for bone marrow dosi...

Metaiodobenzylguanidine (MIBG) imaging has been the standard for neuroblastoma staging many decades. Novel agents such as 18F-DOPA and 68Ga-DOTATATE are being used nowadays in academic centers. During coronavirus disease 2019 (COVID-19) pandemic, procurement of 123I-MIBG proved particularly challenging, necessitating use PET. is Food Drug Administration–approved...

Introduction: Optimized production and quality control of 68Ga-DOTATATE as an efficient and preferable PET radiotracer for somatostatin receptor imaging in neuroendocrine tumors is of great interest. In this study effort has been made to present a fast, efficient, cost-effective and facile protocol for 68Ga-DOTATATE productions for clinical trials. Methods:68Ga...